Domperidone for young people with gastroparesis or reflux that other treatments did not help
Offers domperidone to young people with gastroparesis or GERD when standard treatments failed.
Key facts
- Who runs it
- Jose Cocjin
- Where
- Kansas City, United StatesSee the site
- Trial code
- Registry title
- Compassionate Use of Domperidone for Refractory Gastroparesis
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- Apr 2013
- Expected to end
- Dec 2035
- Type of study
- Interventional
- Treatments tested
- Domperidone
- Record updated
- 24 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young people aged 12 to 21 with reflux (GERD) or gut movement problems. Their symptoms must not have improved with standard treatments. They will receive domperidone.
- Age
- 12 to 21 years
- Sex
- All sexes
- Disease stage
- Symptoms from GERD (such as ongoing inflammation of the food pipe, heartburn, airway or breathing symptoms) or gut movement disorders (such as nausea, vomiting, severe indigestion or severe long-term constipation). The symptoms have not improved with standard therapy.
- Earlier treatment
- Standard treatments must have failed. A full check-up must have ruled out other causes of the symptoms.
Main reasons for not taking part
- Past or current heart rhythm problems, such as ventricular tachycardia, ventricular fibrillation or Torsade des Pointes
- Slow heart rate, heart block, or long QTc (over 450 milliseconds in males, over 470 milliseconds in females)
- Serious problems with blood salts (electrolytes)
- Bleeding or blockage in the gut, or a prolactinoma (a pituitary tumour that releases prolactin)
- Pregnancy, breastfeeding, or known allergy to domperidone
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Male or female
- Age 12 - 21
- Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy
- Patients must have a comprehensive evaluation to eliminate other causes of their symptoms
- Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:; increased prolactin levels; extrapyramidal side effects; breast changes; Cardiac arrhythmias including QT prolongation; There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25); The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements
Who cannot take part
- History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded
- Clinically significant electrolyte disorders
- Gastrointestinal hemorrhage or obstruction
- Known allergy to domperidone
- Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc> 450 milliseconds for males, QTc>470 milliseconds for females)
- Presence of a prolactinoma (prolactin-releasing pituitary tumor)
- Pregnant or breast feeding female
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 12 and 21 years old?
Where in United States
- Children's Mercy Hospitals and ClinicsKansas City, United StatesContact: Corey Schurman, MATaking people
About the trial
What the trial wants to find out
The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.
The group in the trial
- Overall StudyOther group
Receive domperidone 4 times a day, weight-dependent dose
Treatment: Domperidone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Compassionate Use of Domperidone for Refractory Gastroparesis
- Plain-language title
- Domperidone for young people with gastroparesis or reflux that other treatments did not helpGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT04699591, who can take part
- Record updated
- 24 March 2026